75 related articles for article (PubMed ID: 9380591)
1. Management of patients receiving transperineal palladium-103 prostate implants.
Cash JC; Dattoli MJ
Oncol Nurs Forum; 1997 Sep; 24(8):1361-7. PubMed ID: 9380591
[TBL] [Abstract][Full Text] [Related]
2. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
3. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
4. Erectile function outcome reporting after clinically localized prostate cancer treatment.
Burnett AL; Aus G; Canby-Hagino ED; Cookson MS; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus S; Liebert M; Moul JW; Tangen C; Thrasher JB; Thompson I;
J Urol; 2007 Aug; 178(2):597-601. PubMed ID: 17570435
[TBL] [Abstract][Full Text] [Related]
5. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
6. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
7. Nursing assessment of sexual function following permanent prostate brachytherapy for patients with early-stage prostate cancer.
Stipetich RL; Abel LJ; Blatt HJ; Galbreath RW; Lief JH; Butler WM; Merrick GS
Clin J Oncol Nurs; 2002; 6(5):271-4. PubMed ID: 12240487
[TBL] [Abstract][Full Text] [Related]
8. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
9. Nursing considerations in brachytherapy-related erectile dysfunction.
Stipetich R; Abel LJ; Anderson RL; Butler WM; Wallner KE; Merrick GS
Urol Nurs; 2005 Aug; 25(4):249-54; quiz 259. PubMed ID: 16225341
[TBL] [Abstract][Full Text] [Related]
10. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
11. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
12. Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy.
Dauer LT; Zelefsky MJ; Horan C; Yamada Y; St Germain J
Brachytherapy; 2004; 3(1):1-6. PubMed ID: 15110306
[TBL] [Abstract][Full Text] [Related]
13. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005.
Colberg JW; Decker RH; Khan AM; McKeon A; Wilson LD; Peschel RE
Cancer J; 2007; 13(4):229-32. PubMed ID: 17762756
[TBL] [Abstract][Full Text] [Related]
14. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
15. Success of sildenafil for erectile dysfunction in men treated with brachytherapy or external beam radiation for prostate cancer.
Shemtov OM; Radomski SB; Crook J
Can J Urol; 2004 Dec; 11(6):2450-5. PubMed ID: 15636671
[TBL] [Abstract][Full Text] [Related]
16. Epididymitis after prostate brachytherapy.
Hoffelt SC; Wallner K; Merrick G
Urology; 2004 Feb; 63(2):293-6. PubMed ID: 14972474
[TBL] [Abstract][Full Text] [Related]
17. The effect on erectile function of 103palladium implantation for localized prostate cancer.
Ponholzer A; Oismüller R; Somay C; Büchler F; Maier U; Hawliczek R; Rauchenwald M; Madersbacher S
BJU Int; 2005 Apr; 95(6):847-50. PubMed ID: 15794796
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity.
Blank KR; Whittington R; Arjomandy B; Wein AJ; Broderick G; Staley J; Malkowicz SB
Cancer J Sci Am; 1999; 5(6):370-3. PubMed ID: 10606479
[TBL] [Abstract][Full Text] [Related]
19. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R
Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905
[TBL] [Abstract][Full Text] [Related]
20. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
